NeoGenomics Management
Management criteria checks 2/4
NeoGenomics' CEO is Chris Smith, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is $11.67M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.47% of the company’s shares, worth $8.41M. The average tenure of the management team and the board of directors is 1.6 years and 3.3 years respectively.
Key information
Chris Smith
Chief executive officer
US$11.7m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues
Mar 30
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking
Dec 26Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Aug 23Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)
Jul 16NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
Apr 18We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt
Jan 10NeoGenomics: Market Punishment Continues, But Looks Justified
Sep 30NeoGenomics grants CEO restricted shares, stock options
Aug 17Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Aug 10NeoGenomics rises ~14% on strong Q2 result
Aug 09NeoGenomics gets new CEO
Jul 21NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential
Jun 28Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Apr 22Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral
Apr 08Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching
Feb 11Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
Jan 07NeoGenomics: Gambling On Growth
Dec 16NeoGenomics: Profitability Headwinds Compress Valuation, Shares
Sep 28Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Sep 24NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing
Jul 02NeoGenomics completes Inivata acquisition
Jun 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$84m |
| Dec 31 2023 | US$12m | US$1m | -US$88m |
| Sep 30 2023 | n/a | n/a | -US$96m |
| Jun 30 2023 | n/a | n/a | -US$115m |
| Mar 31 2023 | n/a | n/a | -US$126m |
| Dec 31 2022 | US$15m | US$346k | -US$144m |
Compensation vs Market: Chris's total compensation ($USD11.67M) is above average for companies of similar size in the US market ($USD5.72M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Smith (60 yo)
1.8yrs
Tenure
US$11,665,946
Compensation
Mr. Christopher Michael Smith, also known as Chris, serves as Chief Executive Officer at NeoGenomics Laboratories, Inc. since August 2022. He serves as Director at NeoGenomics Laboratories, Inc. since 2023...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$11.67m | 0.47% $ 8.4m | |
| Chief Financial Officer | 1.4yrs | US$3.55m | 0.098% $ 1.8m | |
| President of Advanced Diagnostics | 2.3yrs | US$2.37m | 0.10% $ 1.8m | |
| President & COO of Informatics | 1.4yrs | US$4.69m | 0.081% $ 1.4m | |
| Chief Commercial Officer | 1.5yrs | US$3.01m | 0.066% $ 1.2m | |
| Chief Accounting Officer | less than a year | no data | 0.012% $ 214.8k | |
| Vice President of Investor Relations & Communications | no data | no data | no data | |
| Executive VP of Business Development | 2.1yrs | no data | 0.027% $ 486.9k | |
| Chief Compliance Officer | 2.1yrs | no data | no data | |
| Chief Medical Officer | 3.3yrs | no data | no data | |
| Chief Culture Officer | 1.3yrs | no data | no data | |
| Director of Clinical Science | no data | no data | no data |
1.6yrs
Average Tenure
52yo
Average Age
Experienced Management: NEO's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$11.67m | 0.47% $ 8.4m | |
| Independent Director | 3.8yrs | US$317.50k | 0.016% $ 285.1k | |
| Independent Director | 9.6yrs | US$313.45k | 0.051% $ 909.4k | |
| Independent Chair of the Board | 8.9yrs | US$365.00k | 0.044% $ 784.5k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | less than a year | US$276.23k | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 6.8yrs | US$309.20k | 0.019% $ 345.7k | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of Scientific Advisory Board & Independent Director | 8.9yrs | US$305.00k | 0.084% $ 1.5m | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: NEO's board of directors are considered experienced (3.3 years average tenure).